Aytu BioPharma (NASDAQ:AYTU) Stock Rating Upgraded by Zacks Research

Aytu BioPharma (NASDAQ:AYTU) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Several other research firms have also issued reports on AYTU. Ascendiant Capital Markets lifted their target price on shares of Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Friday, January 9th. Finally, Wall Street Zen raised Aytu BioPharma to a “hold” rating in a report on Saturday, February 7th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Aytu BioPharma currently has an average rating of “Hold” and an average price target of $9.33.

Aytu BioPharma Stock Performance

Shares of AYTU stock opened at $2.64 on Monday. The company’s fifty day moving average price is $2.52 and its 200-day moving average price is $2.33. The stock has a market cap of $28.33 million, a PE ratio of -0.69 and a beta of 0.35. The company has a current ratio of 1.16, a quick ratio of 1.03 and a debt-to-equity ratio of 0.70. Aytu BioPharma has a 12 month low of $0.95 and a 12 month high of $3.07.

Aytu BioPharma (NASDAQ:AYTU) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.79). Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%. The business had revenue of $15.17 million for the quarter, compared to analysts’ expectations of $12.17 million.

Institutional Trading of Aytu BioPharma

Several institutional investors have recently added to or reduced their stakes in the business. Daytona Street Capital LLC purchased a new position in shares of Aytu BioPharma in the fourth quarter worth $26,000. Persistent Asset Partners Ltd boosted its position in shares of Aytu BioPharma by 27.2% during the fourth quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock valued at $206,000 after buying an additional 16,963 shares during the last quarter. Rothschild Wealth LLC bought a new stake in Aytu BioPharma in the 4th quarter worth about $52,000. Bellevue Asset Management LLC purchased a new position in Aytu BioPharma in the 4th quarter worth about $65,000. Finally, XTX Topco Ltd bought a new position in Aytu BioPharma during the 4th quarter valued at about $67,000. 33.49% of the stock is currently owned by hedge funds and other institutional investors.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.